Citation

Demler TL. U.S. Pharmacist 2019; 44(9): 36-44.

Copyright

(Copyright © 2019)

DOI

unavailable

PMID

unavailable

Abstract

Postpartum depression (PPD), a serious mental health condition, can have significant adverse effects on both mother and infant. This mood disorder often goes unrecognized, and even when it is diagnosed, PPD may be undertreated owing to prescriber and patient concerns about the safety risks associated with the agents used for treatment. In addition to keeping abreast of new medications approved for PPD treatment, it is imperative that pharmacists become fluent in interpreting the pregnancy and lactation risks of medications; additionally, they must offer patient education that supports shared decision making and emphasize the importance of adherence to the drug once a regimen has been initiated. © 2019, Jobson Publishing Corporation. All rights reserved.

Language: en

Keywords

United States; human; suicide; patient safety; risk assessment; pharmacist; risk factor; pregnancy; antidepressant agent; continuing education; disease course; breast feeding; Article; lactation; postnatal depression; prepregnancy care; obstetric delivery; brexanolone; risk evaluation and mitigation strategy